ARDELYX, INC. Proceeds from Debt, Net of Issuance Costs
ARDELYX, INC. (ARDX) reported Proceeds from Debt, Net of Issuance Costs of $49.29 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2021-03-08
- ARDELYX, INC. proceeds from debt, net of issuance costs for the quarter ending 2018-12-31 was $0.00.
- ARDELYX, INC. proceeds from debt, net of issuance costs for the quarter ending 2018-09-30 was $0.00.
- ARDELYX, INC. proceeds from debt, net of issuance costs for fiscal 2018 was $49.29M.
| Period end | Proceeds from Debt, Net of Issuance Costs | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $0.00 derived: sum of 2 quarters · filed 2021-03-08 | $49.29M 10-K · filed 2021-03-08 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $49.29M 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | $49.29M 10-Q · filed 2019-08-09 | ||||
| 2018-05-16 | $49.30M 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |